0.8154
前日終値:
$0.82
開ける:
$0.8766
24時間の取引高:
1.18M
Relative Volume:
0.59
時価総額:
$150.41M
収益:
$90.12M
当期純損益:
$-276.06M
株価収益率:
-0.5585
EPS:
-1.46
ネットキャッシュフロー:
$-193.47M
1週間 パフォーマンス:
-5.32%
1か月 パフォーマンス:
-8.57%
6か月 パフォーマンス:
-37.76%
1年 パフォーマンス:
-4.07%
Nektar Therapeutics Stock (NKTR) Company Profile
名前
Nektar Therapeutics
セクター
電話
(415) 482-5300
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
NKTR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NKTR
Nektar Therapeutics
|
0.8154 | 150.41M | 90.12M | -276.06M | -193.47M | -1.46 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-08 | 開始されました | B. Riley Securities | Buy |
2024-12-10 | 開始されました | H.C. Wainwright | Buy |
2024-11-04 | 開始されました | Piper Sandler | Overweight |
2024-09-30 | 再開されました | BTIG Research | Buy |
2024-06-28 | 開始されました | Rodman & Renshaw | Buy |
2023-11-20 | 再開されました | JP Morgan | Underweight |
2023-11-09 | アップグレード | TD Cowen | Market Perform → Outperform |
2023-05-10 | アップグレード | Jefferies | Underperform → Hold |
2023-02-24 | ダウングレード | Jefferies | Hold → Underperform |
2022-08-08 | ダウングレード | JP Morgan | Neutral → Underweight |
2022-05-31 | 再開されました | Jefferies | Hold |
2022-04-18 | ダウングレード | Goldman | Neutral → Sell |
2022-03-15 | ダウングレード | Cowen | Outperform → Market Perform |
2022-03-15 | ダウングレード | Mizuho | Buy → Neutral |
2022-03-14 | ダウングレード | BTIG Research | Buy → Neutral |
2022-03-14 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-03-14 | ダウングレード | Stifel | Buy → Hold |
2022-03-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
2022-03-09 | アップグレード | Oppenheimer | Perform → Outperform |
2021-11-08 | アップグレード | The Benchmark Company | Hold → Buy |
2021-09-10 | 開始されました | BofA Securities | Neutral |
2021-06-28 | アップグレード | Stifel | Hold → Buy |
2021-05-18 | 再開されました | Goldman | Neutral |
2021-02-22 | ダウングレード | The Benchmark Company | Buy → Hold |
2021-01-06 | 開始されました | Stifel | Hold |
2020-09-14 | 開始されました | JP Morgan | Neutral |
2020-06-10 | ダウングレード | CFRA | Hold → Sell |
2020-05-12 | 繰り返されました | H.C. Wainwright | Neutral |
2020-04-22 | 開始されました | The Benchmark Company | Buy |
2020-03-30 | アップグレード | Goldman | Sell → Neutral |
2020-03-04 | 開始されました | Barclays | Overweight |
2020-02-03 | アップグレード | Mizuho | Neutral → Buy |
2019-10-24 | 開始されました | Oppenheimer | Perform |
2019-10-08 | ダウングレード | Goldman | Buy → Sell |
2019-08-09 | ダウングレード | JP Morgan | Overweight → Neutral |
2019-08-09 | ダウングレード | Jefferies | Buy → Hold |
2019-08-09 | ダウングレード | Mizuho | Buy → Neutral |
2019-03-15 | 開始されました | SVB Leerink | Mkt Perform |
2018-12-13 | 開始されました | Goldman | Buy |
2018-06-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2018-06-04 | 繰り返されました | H.C. Wainwright | Buy |
2018-04-20 | 開始されました | Seaport Global Securities | Buy |
2018-04-13 | 再開されました | Piper Jaffray | Overweight |
2018-04-06 | 繰り返されました | Mizuho | Buy |
2018-04-02 | 再開されました | H.C. Wainwright | Buy |
すべてを表示
Nektar Therapeutics (NKTR) 最新ニュース
Oppenheimer Upgrades Nektar Therapeutics (NKTR) to Outperform - StreetInsider.com
Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6 - Marketscreener.com
Nektar Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks
BTIG keeps Nektar stock Neutral with $4.00 target By Investing.com - Investing.com Australia
Promising Pipeline and Strategic Positioning: Julian Harrison’s Buy Rating on Nektar Therapeutics - TipRanks
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up - Yahoo Finance
Nektar Therapeutics: Poised for Growth with Promising Rezpeg Study and Market Potential - TipRanks
Assessing Nektar Therapeutics: Insights From 4 Financial Analysts - Benzinga
BTIG keeps Nektar stock Neutral with $4.00 target - Investing.com India
Jefferies cuts Nektar stock target to $1.00, maintains hold - Investing.com India
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Nektar Therapeutics Reports 2024 Financial Progress - TipRanks
Nektar reports Q4 adjusted EPS (15c), consensus (19c) - TipRanks
Nektar: Q4 Earnings Snapshot - San Antonio Express-News
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates - Yahoo Finance
NEKTAR THERAPEUTICS Earnings Results: $NKTR Reports Quarterly Earnings - Nasdaq
Earnings call transcript: Nektar Therapeutics’ Q4 2024 beats EPS expectations, stock surges - Investing.com India
Nektar: Q4 Earnings Snapshot -March 12, 2025 at 06:13 pm EDT - Marketscreener.com
Nektar Therapeutics reports results for the quarter ended December 31Earnings Summary - TradingView
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - Longview News-Journal
Nektar Therapeutics shares rise on Q4 earnings beat By Investing.com - Investing.com Australia
Nektar Therapeutics shares rise on Q4 earnings beat - Investing.com India
Nektar Therapeutics (NKTR) Tops Q4 EPS by 19c - StreetInsider.com
Alopecia Areata Market to Expand Significantly by 2032, States DelveInsight Report | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart
Nektar Therapeutics (NASDAQ:NKTR) Receives $4.08 Consensus PT from Brokerages - Defense World
AstraZeneca selects Daiichi Sankyo as US marketing partner for Movantik - FirstWord Pharma
AstraZeneca, Nektar's Moventig recommended for approval in Europe - FirstWord Pharma
Nektar Therapeutics to Host Earnings Call - ACCESS Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets - Longview News-Journal
Metastatic Melanoma Pipeline 2024: Key Companies, MOA, ROA, - openPR
Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata - MSN
HC Wainwright Reiterates Buy Rating for Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat
Nektar Therapeutics (NKTR) Expected to Announce Earnings on Monday - Defense World
Nektar Therapeutics (NASDAQ:NKTR) Receives "Market Perform" Rating from William Blair - MarketBeat
Bambusa Therapeutics doses first volunteers in Phase I bispecific AD trial - Yahoo Finance
Investor Network: Nektar Therapeutics to Host Earnings Call - ACCESS Newswire
Nektar completes enrollment for alopecia study of rezpegaldesleukin By Investing.com - Investing.com South Africa
Nektar completes enrollment for alopecia study of rezpegaldesleukin - Investing.com India
Nektar Therapeutics (NKTR) Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin - StreetInsider.com
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata - Longview News-Journal
Buy Rating for Nektar Therapeutics: Strategic Collaboration with TrialNet Enhances Rezpeg’s Potential in Type 1 Diabetes - TipRanks
H.C. Wainwright maintains $6.50 target on Nektar stock By Investing.com - Investing.com Canada
H.C. Wainwright maintains $6.50 target on Nektar stock - Investing.com India
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider.com
Piper Sandler maintains $7 target on Nektar stock post-event - Investing.com India
Piper Sandler maintains $7 target on Nektar stock post-event By Investing.com - Investing.com South Africa
Nektar Therapeutics (NKTR) 財務データ
収益
当期純利益
現金流量
EPS
Nektar Therapeutics (NKTR) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Wilson Mark Andrew | Chief Legal Officer |
Feb 19 '25 |
Sale |
1.01 |
11,040 |
11,150 |
324,292 |
ROBIN HOWARD W | President & CEO |
Feb 19 '25 |
Sale |
1.01 |
23,774 |
24,012 |
1,086,901 |
大文字化:
|
ボリューム (24 時間):